The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Q2 2025 Results Conference Call February 6, 2025 10:30 AM ETCompany ParticipantsKellie Smythe - Senior Director ...

There are important distinctions in cancer diagnoses and deaths among different regions of Appalachia, with certain areas ...

How do you measure process work? First introduced in the 19th and early 20th centuries, time and motion studies established ...

Polluted runoff is still smothering the Great Barrier Reef, our first national assessment of water quality trends in ...

Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...

Q4 2024 Earnings Call Transcript February 4, 2025 Apollo Global Management, Inc. beats earnings expectations. Reported EPS is ...

Abstract Research of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia (FM), two acquired chronic illnesses affecting mainly females, has failed to ascertain their frequent ...

Structural variation in the genome can directly or indirectly influence gene dosage through different mechanisms, and therefore influence phenotypic variation and disease. The cataloguing of ...

The locus-specific mutation frequencies for copy number variation and other structural changes are two to four orders of magnitude greater than for point mutations. HR mechanisms generally achieve ...

With GP, VB, and MCMC, they then exhibited a tendency to underestimate κ ... can therefore not only be summarized as point estimates, but also as posterior central intervals (PCIs; the 95% PCI is the ...